Summit Therapeutics is a biopharmaceutical company developing oncology therapies designed to improve patient quality of life and survival outcomes in serious cancers with unmet medical needs. The company's lead candidate is ivonescimab, a novel bispecific antibody that combines PD-1 immunotherapy blockade with anti-angiogenic VEGF inhibition in a single molecule, which Summit is advancing through Phase III clinical trials in non-small cell lung cancer and colorectal cancer. Summit generates revenue through a licensing agreement with Akeso, from which it holds development and commercialization rights across North America, Europe, Japan, Latin America, the Middle East, and Africa; the company earns money through upfront payments, regulatory milestones, annual revenue milestones, and royalties on ivonescimab sales, while outsourcing manufacturing to Akeso and contracted supply partners.